R&D in the “Decade of Vaccines”:

From the “Decade of Vaccines Collaboration” to the Global Vaccine & Immunization Research Forum

B. Fenton Hall, MD, PhD
Chief, Parasitology & International Programs Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH, DHHS

On Behalf of the DoV Collaborating Agencies

GVIRF
4-6 March 2014
Why a “Decade of Vaccines”?

- **Significant impact of immunization in the past decades**
  - Progress with disease elimination or eradication
  - Millions of deaths averted

- **Ability to deliver immunization with high coverage**
  - Already reaching >80% children globally
  - Higher than any other intervention across the continuum of care

- **Increasing number of diseases now vaccine preventable**
  - Robust vaccine pipeline
  - Progress with adding vaccines into national programs

- **Despite many successes, opportunities to do much better**
Mission of the Decade of Vaccines

"ATTAINMENT OF A WORLD IN WHICH ALL PEOPLE AT RISK ARE PROTECTED AGAINST VACCINE-PREVENTABLE DISEASES"

In 2010 a Decade of Vaccines Collaboration (DoVC) was established to coordinate the development of a Global Vaccine Action Plan to provide a framework for accomplishing the mission.
DoV Leadership Council

DR. SETH BERKLEY  
CEO  
GAVI Alliance

DR. MARGARET CHAN  
Director General  
WHO

DR. CHRISTOPHER ELIAS  
President, Global Development Program  
(effective Feb. 1, 2012)  
Bill and Melinda Gates Foundation

DR. ANTHONY FAUCI  
Director  
NIAID

DR. ANTHONY LAKE  
Executive Director  
UNICEF

MS. JOY PHUMAPHI  
Executive Secretary  
African Leaders Malaria Alliance
Outputs of the Decade of Vaccines Collaboration
Decade of Vaccines: Vision & Mission

“We envision a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases.

The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.”
The GVAP Differs Significantly from Prior Vaccine Initiatives

- Explicitly includes an R&D component
  - Basic & Translational
  - Implementation
  - Operational

- Explicitly includes an M&E/Accountability component and framework
World Health Assembly Actions

- Endorsed the GVAP in May 2012 and urged 194 member states to:
  - Apply
  - Commit
  - Report
    - Annually to WHO regional and global governing bodies
      - Regional Committees (Q3-Q4)
      - WHO Executive Board (January)
      - WHA (May)

- Supported the M&E/Accountability Framework in May 2013
“Decade of Vaccines” Supplement

(Vaccine 31, Suppl. 2, 18 April 2013)

- 27 Articles, 210 Authors, 90 Reviewers
- Addresses GVAP Goals and Strategic Objectives
- 9 Case Studies, including:
  - Epstein-Barr Virus,
  - Cytomegalovirus, HIV,
  - Respiratory Syncytial Virus, Group A
  - Streptococci,
  - Tuberculosis, Hookworm,
  - Malaria, Leishmaniasis

www.sciencedirect.com/science/journal/0264410X/31/supp/S2 (open source)
R&D Reporting

- Scheduled to take place every 2 years

- Key areas relate to Strategic Objective 6 and Goal 4 of the GVAP:
  - Expanding capabilities and engagement with end-users;
  - Enabling development of new vaccines;
  - Accelerating development, licensing and uptake of vaccines; and
  - Improving programme efficiencies and increasing coverage.
“Enhanced Collaboration on Research Matters Related to the Global Vaccine Action Plan”

- Memorandum of Understanding signed March 20, 2013 by BMGF, NIAID and WHO
- Provides framework for enhanced collaboration on R&D related to the GVAP

Global Vaccine & Immunization Research Forum

- 4-6 March 2014, Bethesda MD, USA
- First of an ongoing series